Beta-RBD-Fc dimer recombinant protein vaccine
®, RBD
The beta-RBD-Fc dimer consisted of a truncated RBD (N334–P527) linked to the Fc-domain of human IgG1 from the core hinge region through to the C-terminal lysine via a GSGSG linker. DNA encoding this sequence was transfected into CHOK1SV GS-KO® cell lines for stable expression using the Lonza GS Xceed® system. Minipools were generated, and lead minipool selected using Lonza's abridged fed-batch shake flask screen at the National Biologics Facility, University of Queensland, Australia. ISO 9001:2015 standard. Beta-RBD-Fc protein was manufactured at the CSIRO tissue culture facility in Melbourne, Australia. The vaccine was formulated with oil-in-water adjuvant MF59® (CSL Seqirus proprietary adjuvant) at the time of injection.